| Online-Ressource |
Verfasst von: | Bountogo, Mamadou [VerfasserIn]  |
| Zoungrana, Augustin [VerfasserIn]  |
| Coulibaly, Boubacar [VerfasserIn]  |
| Klose, Christina [VerfasserIn]  |
| Mansmann, Ulrich [VerfasserIn]  |
| Mockenhaupt, Frank P. [VerfasserIn]  |
| Burhenne, Jürgen [VerfasserIn]  |
| Mikus, Gerd [VerfasserIn]  |
| Walter-Sack, Ingeborg [VerfasserIn]  |
| Schirmer, Rolf Heiner [VerfasserIn]  |
| Sié, Ali [VerfasserIn]  |
| Meissner, Peter [VerfasserIn]  |
| Müller, Olaf [VerfasserIn]  |
Titel: | Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria |
Titelzusatz: | a controlled trial in Burkina Faso |
Verf.angabe: | Mamadou Bountogo, Augustin Zoungrana, Boubacar Coulibaly, Christina Klose, Ulrich Mansmann, Frank P. Mockenhaupt, Jürgen Burhenne, Gerd Mikus, Ingeborg Walter-Sack, R. Heiner Schirmer, Ali Sié, Peter Meissner, and Olaf Müller |
E-Jahr: | 2010 |
Jahr: | 10 May 2010 |
Umfang: | 5 S. |
Fussnoten: | Gesehen am 15.02.2023 |
Titel Quelle: | Enthalten in: Tropical medicine & international health |
Ort Quelle: | Oxford [u.a.] : Wiley-Blackwell, 1996 |
Jahr Quelle: | 2010 |
Band/Heft Quelle: | 15(2010), 6, Seite 713-717 |
ISSN Quelle: | 1365-3156 |
Abstract: | Objective To assess the efficacy of methylene blue (MB) monotherapy in semi-immune adults with uncomplicated malaria in Burkina Faso. Methods In an open-label controlled phase II study with 60 semi-immune adults with uncomplicated falciparum malaria in Nouna, north-western Burkina Faso, MB monotherapy (390 mg twice daily) was given sequentially to groups of 20 adults for 7 days (MB7), 5 days (MB5) and 3 days (MB3), respectively. The primary outcome was the rate of adequate clinical and parasitological response (ACPR) on day 28 of follow-up. Results Of the study population, 27/58 (47%) and 5/51 (10%) patients still had parasites on days 2 and 3, respectively, of follow-up resulting in 9/58 (16%) early treatment failures. By day 14, no recrudescence was observed but in 4/19 (MB5) and 2/20 (MB3) individuals by day 28. The PCR-corrected rate of ACPR was 72%, 58% and 85% in groups 7, 5 and 3, respectively, by per protocol analysis. Self-limiting dysuria was the most frequent adverse event. Conclusions MB acts slowly against the blood stages of P. falciparum. MB alone needs to be given for at least 7 days to be efficacious in the treatment of falciparum malaria but should be used in combination with a fast acting antimalarial. |
DOI: | doi:10.1111/j.1365-3156.2010.02526.x |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1111/j.1365-3156.2010.02526.x |
| Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-3156.2010.02526.x |
| DOI: https://doi.org/10.1111/j.1365-3156.2010.02526.x |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Africa |
| África |
| Afrique |
| azul de metileno |
| bleu de méthylène |
| burkina Faso |
| Burkina Faso |
| burkina-Faso |
| efficacité |
| efficacy |
| eficacia |
| falciparum malaria |
| malaria falciparum |
| malaria por falciparum |
| methylene blue |
K10plus-PPN: | 1835701175 |
Verknüpfungen: | → Zeitschrift |
Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria / Bountogo, Mamadou [VerfasserIn]; 10 May 2010 (Online-Ressource)